

Ref. No: 0598
Date: 16/01/24
Subject: Intra-Vitreous Injections / Implants

REQUEST

1. How many of the following intra-vitreous injections / implants has your Trust administered in the four-month period from September to December 2023:

- Aflibercept
- Bevacizumab – Avastin
- Bevacizumab – Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab – Lucentis (pre-filled syringes)
- Ranibizumab – Lucentis (vials)
- Ranibizumab – Ongavia

2. Please provide the number of injections / implants by eye condition for the four-month period from September to December 2023:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept			
Bevacizumab			
Dexamethasone			
Faricimab			
Ranibizumab - Lucentis			
Ranibizumab - Ongavia			

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. How many of the following intra-vitreous injections / implants has your Trust administered in the four-month period from September to December 2023:

Treatment	No. Patients
Aflibercept	689
Bevacizumab – Avastin	0
Bevacizumab – Biosimilar	0
Brolucizumab	0
Dexamethasone	27
Faricimab	233
Fluocinolone acetonide	0
Ranibizumab – Lucentis (pre-filled syringes)	310
Ranibizumab – Lucentis (vials)	0
Ranibizumab – Ongavia	172

2. Please provide the number of injections / implants by eye condition for the four-month period from September to December 2023:

Treatment	Eye Conditions		
	wAMD	DMO	RVO
Aflibercept	523	71	95
Bevacizumab	0	0	0
Dexamethasone	0	9	18
Faricimab	185	48	0
Ranibizumab - Lucentis	216	33	61
Ranibizumab - Ongavia	121	20	31